Thorsten Lehr - Concepedia

Author

Thorsten Lehr

Also Known As

Jeffrey Friedman, Karl-Heinz Liesenfeld, Lehr Thorsten, Lisa Cronin, T Lehr, T. LEHR, T. Lehr, Thorsten Lehr, Throsten Lehr

192

Publications

6.3K

Citations

H-Index

146

Concepts

All Affiliations

Saarland University Boehringer Ingelheim (Germany)University of Tübingen Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Heidelberg University

About

Thorsten Lehr is an author at Saarland University specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	37	3.7K
2	Health Sciences	3	3	68
3	Engineering	2	2	24
4	Education	1	1	47
5	Management	1	1	11

Thorsten Lehr

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients Paul Reilly, Thorsten Lehr, Sebastian Haertter, Journal of the American College of Cardiology ThrombosisDabigatran Plasma ConcentrationsIschemic StrokeCardiovascular DiseaseMedicine	2013	814
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson, The Lancet Drug SafetyAdverse Drug ReactionsPharmacoepidemiologyPharmacologyPharmacogenomics	2023	462
A reference map of potential determinants for the human serum metabolome Noam Bar, Tal Korem, Omer Weissbrod, Nature Reference MapHuman Serum MetabolomeMedicinePhysiologyBioanalysis	2020	427
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study Pavel Bogomolov, A. A. Alexandrov, M. V. Macievich, Journal of Hepatology Chronic Hepatitis DHepatologyViral HepatitisImmunologyFirst Results	2016	380
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial Karl‐Heinz Liesenfeld, Thorsten Lehr, C. Dansirikul, Journal of Thrombosis and Haemostasis ThrombosisCardiovascular DiseaseMedicineHematologyCardiovascular Pharmacology	2011	302
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding Guillaume Paré, Niclas Eriksson, Thorsten Lehr, Circulation	2013	253
First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B Antje Blank, Christoph Markert, Nicolas Hohmann, Journal of Hepatology Novel Hepatitis BFirst-in-human ApplicationViral HepatitisMedicineImmunology	2016	214
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN) Frans Van de Werf, Martina Brueckmann, Stuart J. Connolly, American Heart Journal ThrombosisHeart Valve ReplacementCardiovascular DiseaseDabigatran EtexilateCardiovascular Pharmacology	2012	188
PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin Nina Hanke, Sebastian Frechen, Daniel Moj, CPT Pharmacometrics & Systems Pharmacology	2018	158
Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation Thorsten Lehr, Sebastian Haertter, Karl‐Heinz Liesenfeld, The Journal of Clinical Pharmacology	2011	96

Page 1